BRPI1008855A2 - derivados de indol como agentes anticâncer - Google Patents
derivados de indol como agentes anticâncerInfo
- Publication number
- BRPI1008855A2 BRPI1008855A2 BRPI1008855A BRPI1008855A BRPI1008855A2 BR PI1008855 A2 BRPI1008855 A2 BR PI1008855A2 BR PI1008855 A BRPI1008855 A BR PI1008855A BR PI1008855 A BRPI1008855 A BR PI1008855A BR PI1008855 A2 BRPI1008855 A2 BR PI1008855A2
- Authority
- BR
- Brazil
- Prior art keywords
- anticancer agents
- indole derivatives
- indole
- derivatives
- anticancer
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09152089.0 | 2009-02-04 | ||
| EP09152089 | 2009-02-04 | ||
| PCT/EP2010/051316 WO2010089327A2 (en) | 2009-02-04 | 2010-02-03 | Indole derivatives as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1008855A2 true BRPI1008855A2 (pt) | 2016-03-15 |
| BRPI1008855B1 BRPI1008855B1 (pt) | 2020-05-12 |
| BRPI1008855B8 BRPI1008855B8 (pt) | 2021-05-25 |
Family
ID=40738626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008855A BRPI1008855B8 (pt) | 2009-02-04 | 2010-02-03 | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8541442B2 (pt) |
| EP (1) | EP2393801B1 (pt) |
| JP (1) | JP5612611B2 (pt) |
| KR (1) | KR101730407B1 (pt) |
| CN (1) | CN102307868B (pt) |
| AR (1) | AR075235A1 (pt) |
| AU (1) | AU2010210178B2 (pt) |
| BR (1) | BRPI1008855B8 (pt) |
| CA (1) | CA2749209C (pt) |
| CL (1) | CL2011001860A1 (pt) |
| CO (1) | CO6341625A2 (pt) |
| EA (1) | EA021883B1 (pt) |
| ES (1) | ES2639752T3 (pt) |
| IL (1) | IL214427A (pt) |
| MX (1) | MX2011008195A (pt) |
| MY (1) | MY152018A (pt) |
| NO (1) | NO20111199A1 (pt) |
| NZ (1) | NZ594186A (pt) |
| SG (1) | SG173495A1 (pt) |
| TW (1) | TWI476189B (pt) |
| UA (1) | UA107455C2 (pt) |
| WO (1) | WO2010089327A2 (pt) |
| ZA (1) | ZA201105695B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2841517B2 (ja) | 1989-08-11 | 1998-12-24 | 株式会社ツムラ | 入浴剤 |
| JP2872763B2 (ja) | 1990-06-28 | 1999-03-24 | 紀伊産業株式会社 | 携帯用肛門洗浄器 |
| WO2013063492A1 (en) | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| US9719970B2 (en) | 2012-11-30 | 2017-08-01 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin D metabolites |
| CN113480530A (zh) | 2016-12-26 | 2021-10-08 | 阿里根公司 | 芳香烃受体调节剂 |
| CN106632303A (zh) * | 2017-01-09 | 2017-05-10 | 湖南华腾制药有限公司 | 一种6‑噻唑基吲哚衍生物的制备方法 |
| JP2021503498A (ja) | 2017-11-20 | 2021-02-12 | アリアジェン，インコーポレイテッド | アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物 |
| CN108659003B (zh) * | 2018-04-14 | 2021-01-26 | 上海朝晖药业有限公司 | 一种治疗口腔溃疡的化合物的制备方法 |
| EP3907218A4 (en) * | 2019-01-04 | 2022-09-21 | Jiangsu Hengrui Medicine Co., Ltd. | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE |
| CN112996776B (zh) * | 2019-02-20 | 2024-03-15 | 福建盛迪医药有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| CN113906021A (zh) | 2019-04-15 | 2022-01-07 | 阿里根公司 | 手性吲哚化合物及其用途 |
| WO2024102758A2 (en) * | 2022-11-08 | 2024-05-16 | The General Hospital Corporation | N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| AUPO863197A0 (en) | 1997-08-18 | 1997-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Novel derivatives |
| US6309492B1 (en) | 1998-09-16 | 2001-10-30 | Marc A. Seidner | Polymer fill coating for laminate or composite wood products and method of making same |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| TR200101549T2 (tr) | 1998-12-02 | 2001-11-21 | Pfizer Products Inc. | p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar. |
| WO2001042224A1 (en) | 1999-12-09 | 2001-06-14 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| DE60137435D1 (de) | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| CZ305838B6 (cs) * | 2001-03-29 | 2016-04-06 | Eli Lilly And Company | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 |
| AU2002357728A1 (en) | 2001-11-09 | 2003-05-19 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
| CA2466055A1 (en) | 2001-11-13 | 2003-05-22 | 3-Dimensional Pharmaceuticals, Inc. | Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| DE60225719T2 (de) | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
| GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| NZ553646A (en) * | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| AU2007228784B2 (en) | 2006-03-22 | 2012-03-08 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53 |
| JP5385125B2 (ja) | 2006-03-22 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| US20100129933A1 (en) * | 2007-04-26 | 2010-05-27 | Forschungszentrum Karlsruhe Gmbh | Method for detecting the binding between mdm2 and the proteasome |
| PA8792401A1 (es) | 2007-08-06 | 2009-03-31 | Janssen Pharmaceutica Nv | Fenilendiaminas |
| JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| WO2009037343A1 (en) | 2007-09-21 | 2009-03-26 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
-
2010
- 2010-02-03 AU AU2010210178A patent/AU2010210178B2/en not_active Ceased
- 2010-02-03 KR KR1020117020348A patent/KR101730407B1/ko not_active Expired - Fee Related
- 2010-02-03 AR ARP100100298A patent/AR075235A1/es unknown
- 2010-02-03 BR BRPI1008855A patent/BRPI1008855B8/pt not_active IP Right Cessation
- 2010-02-03 JP JP2011548674A patent/JP5612611B2/ja not_active Expired - Fee Related
- 2010-02-03 TW TW099103103A patent/TWI476189B/zh not_active IP Right Cessation
- 2010-02-03 EP EP10702310.3A patent/EP2393801B1/en active Active
- 2010-02-03 EA EA201170997A patent/EA021883B1/ru not_active IP Right Cessation
- 2010-02-03 NZ NZ594186A patent/NZ594186A/xx not_active IP Right Cessation
- 2010-02-03 CA CA2749209A patent/CA2749209C/en active Active
- 2010-02-03 SG SG2011055431A patent/SG173495A1/en unknown
- 2010-02-03 MX MX2011008195A patent/MX2011008195A/es active IP Right Grant
- 2010-02-03 MY MYPI2011003583 patent/MY152018A/en unknown
- 2010-02-03 WO PCT/EP2010/051316 patent/WO2010089327A2/en not_active Ceased
- 2010-02-03 CN CN201080007001.9A patent/CN102307868B/zh not_active Expired - Fee Related
- 2010-02-03 ES ES10702310.3T patent/ES2639752T3/es active Active
- 2010-02-03 US US13/147,707 patent/US8541442B2/en not_active Expired - Fee Related
- 2010-03-02 UA UAA201109449A patent/UA107455C2/uk unknown
-
2011
- 2011-07-12 CO CO11087033A patent/CO6341625A2/es not_active Application Discontinuation
- 2011-08-02 CL CL2011001860A patent/CL2011001860A1/es unknown
- 2011-08-02 ZA ZA2011/05695A patent/ZA201105695B/en unknown
- 2011-08-03 IL IL214427A patent/IL214427A/en active IP Right Grant
- 2011-09-02 NO NO20111199A patent/NO20111199A1/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300018I1 (hu) | Rákellenes hatású kinoli-8-szulfonamid-származékok | |
| BRPI1008855A2 (pt) | derivados de indol como agentes anticâncer | |
| ES2643164T3 (es) | Indol 7-sustituido como inhibidores de Mcl-1 | |
| PT2566327T (pt) | Indoles | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| GB0905328D0 (en) | Indole derivatives | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
| BR112012002662A2 (pt) | derivados de bis-benzimidazol | |
| BR112012004969A2 (pt) | derivados de bis-benzimidazol | |
| BRPI1008899A2 (pt) | derivados 3,3´-espiroindolinona como agentes anticâncer | |
| BR112013015234A2 (pt) | derivados fosforosos como moduladores de receptor de quimiocina | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| BRPI1014077A2 (pt) | Derivados de tiazolilperidina como fungicidas | |
| IL207684A0 (en) | Substituted indole derivatives | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| BRPI0914942A2 (pt) | Compostos de oxindol | |
| BRPI0809221A2 (pt) | indol carboxamidas como inibidores de ikk2 | |
| BRPI0915887A2 (pt) | derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| BR112013013037A2 (pt) | derivados de indol como moduladores dos receptores de s1p | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| ECSP12011977A (es) | Derivados de etinilo | |
| BRPI1007369A2 (pt) | derivados de di-hidroquinolinona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2760 DE 28-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |